BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs2300478
,
CYP51
,
cell-cell adhesion
,
Allergy to pollen
,
Breast
,
Lipopolysaccharide
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
Deferasirox
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Colorectal cancer SW 480 cells treated with iron chelators deferasirox or desferrioxamine
Cerebrocortical cells treated with blood-brain barrier penetrant clinic-tested drugs
Transcriptional profiling of ICL670 treated K562 cells
Explore Curated Studies Results
Literature
Most Relevant Literature
Evidence for the Metabolic Activation of Deferasirox In Vitro and In Vivo.
Deferasirox: A comprehensive drug profile.
Potential anticancer effect of free and nanoformulated Deferasirox for breast cancer treatment: in-v…
Design, synthesis and evaluation of novel deferasirox derivatives with high antifungal potency in vi…
Crushing tablets or sprinkling capsules: Implications for clinical strategy and study performance ba…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
Pilot Study for Patients With Poor Response to Deferasirox
Safety, Tolerability, and Efficacy of Deferasirox in MDS
Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia
Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ